Please select the option that best describes you:
Would you offer zolbetuximab + chemotherapy in a presumed metastatic duodenal bulb adenocarcinoma with 80% Claudin18.2 expression?
Anatomically, the primary tumor is in the duodenum but extends into the gastric pylorus. Would Zolbetuximab be reasonable to offer with FOLFOX, rather than - say Avastin?
Answer from: Medical Oncologist at Academic Institution
I would not. Cancers of the duodenum are different and such patients were not represented in GLOW or SPOTLIGHT. In addition, zolbe is not very easy in terms of nausea and vomiting, especially in the first cycle. Would not expect more "debulking" effect from it given the absence of significant ORR be...
Sign in or Register to read more